A Cost-Effectiveness Analysis of Rivaroxaban Compared to Warfarin for the Management of Venous Thromboembolism in Western Kenya
In this study, rivaroxaban is a clinically and economically superior alternative to warfarin. This research may catalyze further discussions with policymakers and industry partners to scale up the appropriate use of rivaroxaban in resource-constrained settings.
Authors
- Sonak Pastakia (ORCID: https://orcid.org/0000-0003-4259-695X)
- I Manji (ORCID: https://orcid.org/0000-0001-8715-9804)
- Emily O’Neill (ORCID: https://orcid.org/0000-0002-8071-7997)
- Samuel Nyanje
- Gabriel Kigen (ORCID: https://orcid.org/0000-0002-5047-4066)
- Naftali Busakhala (ORCID: https://orcid.org/0000-0002-1229-3475)
- Andrew W. Huang (ORCID: https://orcid.org/0000-0001-7552-7091)
- Marta Wilson‐Barthes (ORCID: https://orcid.org/0000-0002-9845-7142)
- Omar Galárraga (ORCID: https://orcid.org/0000-0002-9985-9266)
Institutions
- University of Indianapolis (US)
- Moi University (KE)
- Brown University (US)
- Department of Health Services (NP)
- AMPATH (KE)
- Department of Health Services (US)
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Clinical Drug Investigation
- Published
- 2025-06-28
- DOI
- https://doi.org/10.1007/s40261-025-01454-7
- Citations
- 2
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.74